ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE

Post-LOE

acetaminophen; caffeine; dihydrocodeine bitartrate

Passkey Therapeutics

ANDAORALTABLET

Approved

Sep 2016

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE (acetaminophen; caffeine; dihydrocodeine bitartrate) by Passkey Therapeutics is clinical pharmacology acetaminophen, caffeine and dihydrocodeine bitartrate tablets contain dihydrocodeine which is a semi-synthetic narcotic analgesic related to codeine, with multiple actions qualitatively similar to those of codeine; the most prominent of these involve the central nervous system and organs with smooth muscle components. Approved for minor aches, pains due to: headache sore throat flu toothache the common cold temporarily reduces fever. First approved in 2016.

Drug data last refreshed 18h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Acetaminophen, Caffeine and Dihydrocodeine Bitartrate Tablets contain dihydrocodeine which is a semi-synthetic narcotic analgesic related to codeine, with multiple actions qualitatively similar to those of codeine; the most prominent of these involve the central nervous system…

Indications (2)

minor aches pains due to: headache sore throat flu toothache the common cold temporarily reduces fever

Worked on ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE at Passkey Therapeutics? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.